How Much Does Belsomra (Suvorexant) Cost in Oklahoma in 2026?

Oklahoma Retail Pricing: Brand vs. Cash Pay

The gap between what Merck charges and what Oklahomans actually pay at the pharmacy counter is significant. Merck's wholesale acquisition cost for Belsomra sits at $340 per month. Oklahoma retail pharmacies, however, report an average cash-pay price near $85 per month in 2026, a figure driven by discount programs, pharmacy benefit managers, and competitive pricing among chains.

Prices vary by pharmacy and location. Walmart, CVS, and Walgreens locations in Oklahoma City and Tulsa tend to cluster around $80 to $95 for a 30-day supply of Belsomra 10 mg or 20 mg. Independent pharmacies sometimes price higher, though they may offer loyalty discounts. GoodRx and RxSaver coupons can push the effective cost below $75 at select locations. These coupons are free to use and do not require insurance.

Suvorexant received FDA approval in August 2014 as the first dual orexin receptor antagonist (DORA) for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance 1. The key trial by Herring et al. enrolled 3,110 patients with insomnia and demonstrated that suvorexant significantly improved subjective total sleep time by approximately 29 minutes compared to placebo over four weeks 2. That clinical foundation supports its continued use, but the cost question remains front and center for Oklahoma patients paying out of pocket.

Oklahoma Medicaid Does Not Cover Belsomra

Oklahoma Medicaid, administered through SoonerCare, does not include Belsomra on its preferred drug list. Patients enrolled in SoonerCare who need a DORA-class sleep medication face a prior authorization wall that, in practice, results in denial for suvorexant.

The Endocrine Society and the American Academy of Sleep Medicine (AASM) recognize orexin receptor antagonists as a treatment option for chronic insomnia 3. The 2017 AASM clinical practice guideline recommends suvorexant as one of several pharmacologic options when behavioral interventions alone are insufficient. Oklahoma Medicaid, though, steers patients toward older and less expensive alternatives like generic zolpidem (roughly $5 to $15 per month) or trazodone ($4 to $10 per month).

If your prescriber believes suvorexant is medically necessary, a step therapy exception request can be filed through SoonerCare. This requires documentation that the patient has tried and failed at least one preferred agent. Approval rates for these exceptions are low. Most SoonerCare members prescribed a DORA end up with lemborexant (Dayvigo) or no DORA coverage at all.

Commercial Insurance Coverage in Oklahoma

Private insurance plans available in Oklahoma vary widely in their Belsomra coverage. Blue Cross Blue Shield of Oklahoma, for example, places Belsomra on Tier 3 (non-preferred brand) with typical copays running $50 to $75 per month after prior authorization. Aetna plans sold on the Oklahoma ACA marketplace generally require step therapy through zolpidem or eszopiclone before approving suvorexant.

The 2024 Milliman analysis of commercial formulary trends reported that only 38% of commercial plans cover at least one DORA without step therapy requirements 4. That figure is relevant because Oklahoma's insurance market skews toward employers and carriers who adopt restrictive formulary tiers for branded sleep medications.

A few points for Oklahoma patients navigating commercial coverage. First, check your plan's formulary before filling the prescription. A call to the number on the back of your insurance card takes five minutes and can prevent a $340 surprise at the counter. Second, ask your prescriber to submit prior authorization proactively. Third, if your plan denies coverage, appeal the decision. The Oklahoma Insurance Department oversees external review for denied claims, and patients have the right to request independent review under state law.

Prescription drug spending in the U.S. reached $405 billion in 2023, according to CMS data 5. Sleep medications represent a small but growing slice of that total, and Oklahoma patients face the same upward pressure on specialty-tier pricing that affects patients nationwide.

Compounded Suvorexant in Oklahoma: Legal and Available

Oklahoma permits compounded suvorexant through licensed 503A pharmacies. This is legal under both federal and Oklahoma state pharmacy law, provided the compounding pharmacy holds a valid Oklahoma Board of Pharmacy license and compounds pursuant to a valid patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound medications for individual patients when a prescriber determines that a commercially available product does not meet the patient's needs 6. Reasons might include a need for a different dose strength, an allergy to an inactive ingredient in the commercial tablet, or difficulty swallowing tablets.

Compounded suvorexant pricing in Oklahoma varies by pharmacy. Some 503A pharmacies offer compounded formulations at significantly reduced cost compared to the brand product. Patients should verify that any compounding pharmacy they use is licensed by the Oklahoma Board of Pharmacy and that the prescription originates from a licensed prescriber. The Oklahoma Board maintains a searchable database of licensed pharmacies on its website.

One caution: compounded medications do not undergo the same FDA approval process as commercially manufactured drugs. The bioavailability and stability of a compounded suvorexant preparation may differ from the branded Belsomra tablet. Discuss these tradeoffs with your prescriber.

Merck Savings Card and Discount Programs

Merck offers a savings card program for Belsomra that can reduce the copay to as low as $0 per month for eligible commercially insured patients. The program caps annual savings at a set dollar amount (typically $3,400 per year), after which the patient pays the full copay.

Eligibility requirements are straightforward. Patients must have commercial insurance (not Medicare, Medicaid, or any federal or state government program). They must be 18 years or older. The card can be activated online through Merck's patient portal or by calling the number on the Belsomra website. Activation takes roughly two minutes.

For uninsured patients, Merck's patient assistance program (the Merck Helps program) may provide Belsomra at no cost to patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level. In 2026, that threshold for a single individual is approximately $62 to 400 in annual income 7.

Oklahoma patients should also check NeedyMeds and RxAssist, two nonprofit databases that aggregate pharmaceutical assistance programs. Both list the Merck savings card and additional state-specific resources.

Telehealth Prescribing of Belsomra in Oklahoma

Oklahoma law permits prescribing controlled substances, including Schedule IV drugs like suvorexant, via telehealth. The Ryan Haight Act requires at least one in-person medical evaluation before a controlled substance can be prescribed online, though DEA temporary rules during and after the COVID-19 public health emergency modified this requirement. As of 2026, DEA has extended flexibilities for telehealth prescribing of Schedule III through V substances under specific conditions 8.

For Oklahoma patients, this means Belsomra can be prescribed through a telehealth visit with a licensed prescriber, provided the prescriber-patient relationship meets federal and state requirements. Several national telehealth platforms operate in Oklahoma and can prescribe suvorexant after an appropriate evaluation for insomnia.

A telehealth visit for insomnia typically costs $50 to $150 without insurance. Some platforms accept commercial insurance, which may reduce the visit cost to a standard copay. The prescription itself can then be filled at any Oklahoma pharmacy, including mail-order pharmacies, at the prevailing cash or insurance price.

How Suvorexant Works: Mechanism and Dosing

Suvorexant blocks orexin receptors OX1R and OX2R in the hypothalamus, suppressing the wake-promoting orexin signaling system. This mechanism differs fundamentally from benzodiazepines and Z-drugs, which enhance GABA-mediated inhibition. The orexin system was first characterized by de Lecea et al. in 1998 and independently by Sakurai et al. 9. Loss of orexin-producing neurons causes narcolepsy type 1, which confirms the system's role in maintaining wakefulness.

The recommended starting dose is 10 mg taken within 30 minutes of bedtime, with at least 7 hours remaining before the planned time of waking. The dose can be increased to 20 mg if the 10 mg dose is well tolerated but insufficiently effective. The maximum approved dose is 20 mg per night 1.

In the phase 3 trial by Herring et al. (N = 3,110), suvorexant 15/20 mg significantly improved both subjective sleep onset latency and subjective total sleep time compared to placebo at month 1 and month 3 2. The most common adverse effect was somnolence (next-day drowsiness), reported in 7% of suvorexant-treated patients versus 3% of placebo-treated patients. Suvorexant carries a boxed warning for complex sleep behaviors (sleepwalking, sleep-driving), although these events are rare.

Patients taking moderate CYP3A inhibitors (such as diltiazem or erythromycin) should not exceed 5 mg of suvorexant. Strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin) are contraindicated with suvorexant use due to dramatically increased drug exposure 1.

Comparing Suvorexant to Other Oklahoma-Available Insomnia Treatments

Oklahoma patients have several insomnia medication options beyond suvorexant. Generic zolpidem (Ambien) costs $5 to $15 per month and is the most commonly prescribed sleep medication in the state. Eszopiclone (generic Lunesta) runs $15 to $30 per month. Both are Z-drugs with GABA-A receptor mechanisms.

Lemborexant (Dayvigo), the second FDA-approved DORA, costs approximately $350 to $400 per month at list price, with cash-pay prices in Oklahoma near $90 to $110. A meta-analysis by Kishi et al. (2020) compared DORAs head-to-head and found that suvorexant and lemborexant produced similar improvements in total sleep time 10. The choice between them often comes down to insurance formulary placement and cost.

Trazodone, an antidepressant used off-label for insomnia at low doses (25 to 100 mg), costs $4 to $10 per month as a generic. It is the most commonly prescribed off-label sleep aid in the United States, with over 26 million prescriptions dispensed annually for insomnia 11. The evidence base for trazodone in insomnia is thinner than for suvorexant, but its low cost makes it a practical first-line option.

The AASM 2017 guideline does not rank insomnia medications in a strict hierarchy, but recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before any medication 3. Oklahoma residents can access CBT-I through several telehealth platforms at $40 to $80 per session.

Tips for Reducing Your Belsomra Cost in Oklahoma

Start by checking discount platforms. GoodRx, RxSaver, and SingleCare all show real-time pricing at Oklahoma pharmacies. Prices fluctuate weekly, so checking before each refill can save $10 to $20.

If you have commercial insurance, activate the Merck savings card before your first fill. The card stacks on top of your insurance benefit, reducing or eliminating your copay. If you are uninsured and earn below 400% of the federal poverty level, apply for the Merck Helps patient assistance program directly through Merck.

Ask your prescriber about therapeutic alternatives. If cost is the primary barrier, generic zolpidem or trazodone may be clinically appropriate for your insomnia subtype. A prescriber who understands both your clinical profile and your financial situation is in the best position to recommend the right medication.

For patients interested in compounded suvorexant, contact a licensed 503A pharmacy in Oklahoma and ask for pricing. Bring your prescription from a licensed provider. Verify the pharmacy's license status through the Oklahoma Board of Pharmacy's online lookup tool before placing an order.